Abstract 494P
Background
The study aimed to assess the effects of a modified electric field patch operation method on scalp adverse reactions in glioblastoma patients undergoing tumor treating fields (TTFields).
Methods
A total of 73 glioblastoma patients who received TTFields between May 2019 and July 2022 were included in the study. The control group consisted of 36 patients treated with the conventional electric field patch operation method before April 2021, while the modified group included 37 patients treated after May 2021 using an improved technique for adhesion and removal of the electric field patch. The study conducted a comparison between two groups regarding the incidence of adverse scalp reactions and compliance with TTFields.
Results
The modified group exhibited significantly lower rates of scalp pruritus (P=0.0246), contact dermatitis (P=0.0253), and skin ulceration (P=0.0299) compared to the control group. Additionally, compliance with TTFields was notably higher in the modified group (81.1%) than in the control group (52.8%) with a statistically significant difference (P=0.0101). Furthermore, the incidence of adverse scalp reactions displayed seasonal variability, with the highest rates observed in summer (56.16%) and the lowest in winter (8.22%). Following the implementation of the adjusted electric field patch operation technique, a notable decrease in the incidence of adverse scalp reactions during the summer (P=0.0002), autumn (P=0.0411), and spring (P=0.0342) seasons was observed.
Conclusions
The utilization of this modified method has demonstrated efficacy in mitigating scalp adverse reactions, minimizing treatment disruptions, and enhancing adherence to TTFields therapy among patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
586P - Clinical and molecular characteristics of colorectal adenosquamous carcinoma: A multicenter retrospective study
Presenter: Jun Huang
Session: Poster session 16
587P - Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Presenter: Francesco Schietroma
Session: Poster session 16
588P - Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Presenter: Valentino Martelli
Session: Poster session 16
589P - Simultaneous resection versus staged resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study
Presenter: Jianmin Xu
Session: Poster session 16
590P - A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis
Presenter: QingFeng Lin
Session: Poster session 16
Resources:
Abstract
591P - Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Presenter: Joel Kontiainen
Session: Poster session 16
592P - Survival analysis of surgical management options for goblet cell adenocarcinoma: Insights from machine learning clustering
Presenter: Marie Line El Asmar
Session: Poster session 16
593P - Treatment response and survival of patients with early onset colorectal cancer in the Netherlands
Presenter: Lauri Borghuis
Session: Poster session 16
594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Presenter: Annalice Gandini
Session: Poster session 16
595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Presenter: Jerome Desrame
Session: Poster session 16